Get the Stockscreener App
6.045
2.03%
-0.125
Adverum Biotechnologies Inc stock is traded at $6.045, with a volume of 23,202.
It is down -2.03% in the last 24 hours and down -26.82% over the past month.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
See More
Previous Close:
$6.17
Open:
$6.11
24h Volume:
23,202
Relative Volume:
0.12
Market Cap:
$130.43M
Revenue:
-
Net Income/Loss:
$-117.17M
P/E Ratio:
-4.5451
EPS:
-1.33
Net Cash Flow:
$-91.71M
1W Performance:
-16.62%
1M Performance:
-26.82%
6M Performance:
-23.09%
1Y Performance:
-29.71%
1-Day Range:
$6.00
$6.16
1-Week Range:
$6.00
$7.7288
52-Week Range:
$6.00
$29.70
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ADVM | 6.03 | 130.43M | 0 | -117.17M | -91.71M | -1.33 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.05 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.52 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Biotechnologies Grants 55,000 Share Stock Option Package to New Employee | ADVM Stock News - StockTitan
Adverum Biotechnologies (NASDAQ:ADVM) Receives "Buy" Rating from HC Wainwright - MarketBeat
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients (NASDAQ:ADVM) - Seeking Alpha
Adverum Biotechnologies Announces Positive 52-Week LUNA and - GlobeNewswire
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 5.9% in October - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Adverum to present gene therapy data for eye disease - Investing.com India
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - The Manila Times
Adverum to present gene therapy data for eye disease By Investing.com - Investing.com UK
Adverum Biotechnologies Announces Webcast to Report 52-Week - GlobeNewswire
Logos Global Management LP Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
FMR LLC Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is BML Capital Management LLC's 6th Largest Position - MarketBeat
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles By Investing.com - Investing.com Nigeria
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles - Investing.com India
HC Wainwright Issues Pessimistic Forecast for ADVM Earnings - Defense World
Morgan Stanley's Strategic Reduction in Adverum Biotechnologies Inc Shares - GuruFocus.com
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Posts Earnings Results - MarketBeat
Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks
Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate - The Bakersfield Californian
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - StockTitan
Assenagon Asset Management S.A. Has $164,000 Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update - MarketBeat
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adverum Biotechnologies names new chief commercial officer - Investing.com
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief - GlobeNewswire
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - StockTitan
Dimensional Fund Advisors LP Buys 196,884 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Squarepoint Ops LLC Raises Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Purchased by Marshall Wace LLP - MarketBeat
Adverum Biotechnologies to Host Webcast to Review Clinical - GlobeNewswire
ADVM Stock Sees Surge of Approximately 3.49% in Last Five Days - Knox Daily
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance
Logos Global Management LP Sells 1,083,333 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Wall Street SWOT: Adverum Biotechnologies stock faces pivotal year amid trials - Investing.com
Mizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation - MSN
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.17 Average Target Price from Analysts - MarketBeat
(ADVM) Trading Advice - Stock Traders Daily
Logos Global Management LP Cuts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average of $9.52 - MarketBeat
(ADVM) Investment Analysis - Stock Traders Daily
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):